Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy

This project investigates PMC, a novel sterically hindered phenol antioxidant compound, to characterize its protective effects on RPE cells against oxidative damage and to validate its therapeutic efficacy in clinically relevant AMD models.

Late-stage dry age-related macular degeneration (AMD) affects the center of the visual field in the elderly population. Lipid accumulation during AMD promotes oxidative stress that accelerates cellular damage in retinal pigment epithelium (RPE). Our study explores a novel sterically hindered phenol, 2,2,5,7,8-pentamethyl-6- chromanol (PMC), with potent antioxidant properties and ability to reduce RPE degeneration. Our aim is to identify and validate the key mechanisms involved in the therapeutic efficacy of PMC using cell and animal-based models.

This study is the first to systematically evaluate the molecular mechanisms underlying PMC’s (2,2,5,7,8-pentamethyl-6-chromanol) cytoprotective effects across multiple molecular pathways. PMC’s protective mechanisms will be validated in human RPE and patient-derived iPSC-RPE cells carrying clinically relevant AMD-associated risk alleles, bridging bench research and personalized therapeutic development. The CFH H402 transgenic mouse model, closely mirroring the genetic and pathological hallmarks of human AMD, provides a highly translatable platform to assess PMC’s therapeutic efficacy in vivo.

Upon completion, this study will establish PMC (2,2,5,7,8-pentamethyl-6-chromanol) as a promising therapeutic candidate for AMD, a leading cause of irreversible vision loss in the elderly, offering a novel treatment option for millions with limited therapeutic alternatives for dry AMD. Identifying and validating the molecular mechanisms underlying PMC’s protective effects will advance our understanding of oxidative stress induced RPE degeneration, opening new avenues for targeted therapeutic development. These findings from clinically relevant cell and animal models will accelerate pre-clinical and clinical development of PMC based therapeutics.